Cytokinetics And Royalty Pharma Enter Funding Collaboration; Cytokinetics To Receive $50M And Is Eligible To Draw Additional $175M Within 12 Months Of Aficamten Approval, Royalty Will Now Receive 4.5% Up To $5B Of Annual Net Sales Of Aficamten And 1% Above $5B